Kepler Universitätsklinikum

Running trials

• Not yet recruiting

  Phase II Study of Upfront SRT Plus Ivonescimab/Chemotherapy vs Ivonescimab/Chemotherapy in NSCLC Brain Mets

  NCT07234877· Phase 2· European Organisation for Research and Treatment of Cancer - EORTC· Source

• Recruiting

  ABCSG R07 Rectal Cancer Registry

  NCT07780305· Austrian Breast & Colorectal Cancer Study Group· Source

• Recruiting

  A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF

  NCT07761117· Phase 3· AstraZeneca· Source

• Active, not recruiting

  A global study of volrustomig (MEDI5752) plus chemotherapy versus pembrolizumab plus chemotherapy for participants with metastatic non-small cell lung cancer.

  2023-503298-39-00· Phase 3· AstraZeneca AB· Source

• Recruiting

  A Study to Learn More About How Safe Finerenone is, When it is Taken for a Longer Time With Standard Treatment, in Children and Young Adults With Heart Failure and Left Ventricular Systolic Dysfunction

  NCT07192952· Phase 3· Bayer· Source

• Not yet recruiting

  DIRECTION Study

  2025-524495-39-00· Phase 4· Medical University Of Vienna· Source

• Recruiting

  BIO|STREAM.CSP Study

  NCT07393009· Biotronik SE & Co. KG· Source

• Recruiting

  A clinical trial to find out how well LOU064 (remibrutinib) works and how safe it is for people with secondary progressive multiple sclerosis

  2025-521546-23-00· Phase 3· Novartis Pharma AG· Source

• Recruiting

  A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease

  NCT07499232· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  Austrian PBC Registry

  NCT07598669· Medical University of Vienna· Source

• Recruiting

  HYDrochlorothiazidE compared to valsartan to treat arterial hypertension in patients with Hypertrophic obstructive CardioMyopathy – the HYDE-HCM Trial

  2024-520086-31-00· Phase 4· Medical University Of Graz· Source

• Recruiting

  Study of Cabozantinib in Participants With Neuroendocrine Tumors Who Have Already Received Prior Treatment

  NCT07314164· Ipsen· Source

• Recruiting

  A Study to Learn More About How Well Finerenone Works, How Safe it is, and How it Moves Into, Through, and Out of the Body Compared to Placebo When Taken With Standard Treatment in Children With Heart Failure and Left Ventricular Systolic Dysfunction

  NCT07188805· Phase 3· Bayer· Source

• Recruiting

  Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations

  NCT07291037· Phase 3· AstraZeneca· Source

• Recruiting

  A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP

  NCT07091630· Phase 3· argenx· Source

• Recruiting

  A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP

  NCT06920004· Phase 3· argenx· Source

• Recruiting

  Comparison of Four-Channel Functional Electrical Stimulation vs. One-Channel Electrical Stimulation on Moderate Arm/Hand Paresis in Subacute Stroke Patients

  NCT07098572· MED-EL Elektromedizinische Geräte GmbH· Source

• Recruiting

  A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

  NCT06852222· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML

  NCT06652438· Phase 3· Stichting Hemato-Oncologie voor Volwassenen Nederland· Source

• Recruiting

  DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer

  NCT06989112· Phase 3· AstraZeneca· Source

• Recruiting

  A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).

  NCT06646276· Phase 3· Bristol-Myers Squibb· Source

• Recruiting

  Therapeutic Drug Monitoring for Biological Therapy in Pediatric Inflammatory Bowel Disease

  NCT06954311· Medical University Innsbruck· Source

• Recruiting

  A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease

  NCT06227910· Phase 3· Takeda· Source

• Active, not recruiting

  Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)

  NCT06635824· Phase 3· Genmab· Source

• Recruiting

  A Non-interventional, Post-authorisation Safety Study of Patients Treated With Efgartigimod Alfa

  NCT06298565· argenx· Source

• Recruiting

  A Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune Thrombocytopenia

  NCT06544499· Phase 3· argenx· Source

• Active, not recruiting

  LCH-IV International Collaborative Treatment Protocol for Children and Adolescents with Langerhans Cell Histiocytosis

  NCT02205762· Phase 2/3· St. Anna Childrens Cancer Research Institute GmbH· Source

• Recruiting

  A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants with Progressive Pulmonary Fibrosis

  2023-503699-25-00· Phase 3· Bristol-Myers Squibb Services Unlimited Company· Source

• Recruiting

  A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants with Idiopathic Pulmonary Fibrosis

  2023-503697-21-01· Phase 3· Bristol-Myers Squibb Services Unlimited Company· Source

• Active, not recruiting

  MorningLyte: Evaluation of the benefits of the combination of mosunetuzumab plus lenalidomide versus a treatment with anti-CD20 monoclonal antibody plus chemotherapy in subjects with previously untreated FLIPI 2-5 follicular lymphoma

  2023-505436-35-00· Phase 3· Lysarc· Source

• Recruiting

  A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer

  NCT06203210· Phase 3· Daiichi Sankyo· Source

• Recruiting

  Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations

  NCT06357533· Phase 3· AstraZeneca· Source

• Recruiting

  Lomustine With and Without Reirradiation for First Progression of Glioblastoma: a Randomized Phase III Study

  NCT05904119· Phase 3· European Organisation for Research and Treatment of Cancer - EORTC· Source

• Active, not recruiting

  Real-World Study of ABBV-951 Subcutaneous Infusion to Assess Change in Disease Activity in Adult Participants With Parkinson's Disease

  NCT06107426· AbbVie· Source

• Recruiting

  A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma

  NCT06149286· Phase 3· Regeneron Pharmaceuticals· Source

• Active, not recruiting

  A Study of Trastuzumab DeRuxtecan for Patients With Advanced HER2-pOsitive GaStric or GastroesoPhageal Junction AdEnocarcinoma Who Have Received a PrIor Trastuzumab-based Regimen Accompanied by a Disease RegistrY of Patients Treated With Conventional Therapies (PROSPERITY)

  NCT05993234· Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company· Source

• Active, not recruiting

  A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemotherapy for Adult Participants With Follicular Lymphoma

  NCT06097364· Phase 3· Regeneron Pharmaceuticals· Source

• Active, not recruiting

  Phosphatase Inhibition by Intracoronary Gene Therapy in Subjects With Non-Ischemic NYHA Class III Heart Failure

  NCT05598333· Phase 2· AskBio Inc· Source

• Active, not recruiting

  Study of Oral Upadacitinib to Assess Change in Disease Activity in Adult Participants With Ulcerative Colitis

  NCT05496348· AbbVie· Source

• Recruiting

  Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-EB-2

  NCT04628026· Phase 3· University of Ulm· Source

• Active, not recruiting

  Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation

  NCT05243797· Phase 3· European Myeloma Network B.V.· Source

• Recruiting

  A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive-HCM)

  NCT05489705· Bristol-Myers Squibb· Source

• Active, not recruiting

  A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab

  NCT05142696· Phase 1/2· Novartis Pharmaceuticals· Source

• Active, not recruiting

  A Study of Rusfertide in Adults With Polycythemia Vera (PV)

  NCT05210790· Phase 3· Protagonist Therapeutics, Inc.· Source

• Active, not recruiting

  Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-1)

  NCT05147220· Phase 3· Novartis Pharmaceuticals· Source

• Active, not recruiting

  A Study of Guselkumab and Interleukin-17 (IL-17) Inhibitor Therapies in Participants With Psoriatic Arthritis in Routine Clinical Practice

  NCT05049798· Janssen Pharmaceutica N.V., Belgium· Source

• Active, not recruiting

  Evaluation of TAVR Using the NAVITOR Valve in a Global Investigation

  NCT04788888· Abbott Medical Devices· Source

• Active, not recruiting

  Long-Term Observational Study on Effectiveness and Safety of Lecigon in Patients With Advanced Parkinson's Disease

  NCT05043103· Britannia Pharmaceuticals Ltd.· Source

• Active, not recruiting

  The SELUTION DeNovo Study

  NCT04859985· M.A. Med Alliance S.A.· Source

• Active, not recruiting

  Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients

  NCT04824092· Phase 3· Incyte Corporation· Source

Showing 50 of 71.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Childhood cancers5 recruiting
• Heart failure5 recruiting
• Acute myeloid leukaemia4 recruiting
• Lung cancer4 recruiting
• CIDP (chronic inflammatory demyelinating polyneuropathy)2 recruiting
• Crohn's disease2 recruiting
• Hypertrophic cardiomyopathy2 recruiting
• Acute lymphoblastic leukaemia1 recruiting
• Brain metastases1 recruiting
• Chronic rhinosinusitis with nasal polyps1 recruiting
• Colorectal cancer1 recruiting
• Endometrial cancer1 recruiting
• Follicular lymphoma1 recruiting
• Glioblastoma1 recruiting
• High blood pressure1 recruiting
• Immune thrombocytopenia (ITP)1 recruiting
• Liver cirrhosis1 recruiting
• Multiple sclerosis1 recruiting
• Myasthenia gravis1 recruiting
• Myelodysplastic syndromes1 recruiting
• Neuroendocrine tumours1 recruiting
• Primary biliary cholangitis1 recruiting
• Stroke1 recruiting
• Ulcerative colitis1 recruiting

Closed trials

• Completed

  Efficacy and Tolerability of AP707 in Patients with chronic Pain due to Diabetic Polyneuropathy

  2022-500897-32-00· Phase 3· Cannaxan GmbH· Source

• Completed

  Post Market Clinical Follow-up Study for the Amvia/Solvia Pacemaker Family

  NCT06018818· Biotronik SE & Co. KG· Source

• Completed

  Safety and Efficacy of Intra-arterial Tenecteplase for Noncomplete Reperfusion of Intracranial Occlusions

  NCT05499832· Phase 3· Insel Gruppe AG, University Hospital Bern· Source

• Completed

  A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini Stroke

  NCT05686070· Phase 3· Bayer· Source

• Completed

  Different Doses of Naronapride vs. Placebo in Gastroparesis

  NCT05621811· Phase 2· Dr. Falk Pharma GmbH· Source

• Completed

  A study to learn how well the study treatment asundexian works and how safe it is compared to apixaban to prevent stroke or systemic embolism in people with irregular and often rapid heartbeat (atrial fibrillation), and at risk for stroke

  NCT05643573· Phase 3· Bayer AG· Source

• Recruiting

  A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria

  NCT05457283· Phase 3· Bayer· Source

• Active, not recruiting

  A Research Study to Compare Somapacitan Once a Week With Norditropin® Once a Day in Children Who Need Help to Grow

  NCT05330325· Phase 3· Novo Nordisk A/S· Source

• Recruiting

  Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer

  NCT05254171· Phase 2/3· Panbela Therapeutics, Inc.· Source

• Active, not recruiting

  A Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria

  NCT05196035· Phase 3· Bayer· Source

• Active, not recruiting

  Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008/KEYVIBE-008)

  NCT05224141· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  Garadacimab Safety, Pharmacokinetics, and Pharmacodynamics in Idiopathic Pulmonary Fibrosis

  NCT05130970· Phase 2· CSL Behring· Source

• Completed

  Safety and Performance of INVICTA Ventricular DF4 LEADS With Active Fixation-(APOLLO)

  NCT04590144· MicroPort CRM· Source

• Terminated

  HC-1119 Versus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

  NCT03850795· Phase 3· Hinova Pharmaceuticals USA, Inc.· Source

• Completed

  Quality Improvement Project - "My Logbook! - I Know my Way Around!"; ("Mein Logbuch - Ich Kenne Mich Aus!")

  NCT04474678· Medical University of Vienna· Source

• Completed

  Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (PERSEUS)

  NCT04458051· Phase 3· Sanofi· Source

• Completed

  Thoracic RadiothErapy With Atezolizumab in Small Cell lUng canceR Extensive Disease

  NCT04462276· Phase 2· Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest· Source

• Completed

  Phase 3 study of SBRT ± pembrolizumab for participants with unresectable Stage I or II NSCLC

  NCT03924869· Phase 3· Merck Sharp & Dohme Corp.· Source

• Active, not recruiting

  Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients

  NCT03737643· Phase 3· AstraZeneca· Source

• Completed

  Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]

  NCT03734029· Phase 3· Daiichi Sankyo· Source

• Completed

  Non-interventional Study of Ocrelizumab in Participants With Relapsing or Primary Progressive Multiple Sclerosis

  NCT03593590· Hoffmann-La Roche· Source

• Completed

  Confirm Rx Insertable Cardiac Monitor SMART Registry

  NCT03505801· Abbott Medical Devices· Source

• Completed

  Cerebrolysin REGistry Study in Stroke - a High-quality Observational Study of Comparative Effectiveness

  NCT03480698· Ever Neuro Pharma GmbH· Source

• Completed

  Registry of Subjects With Drug Resistant Epilepsy and Treated With the VNS Therapy System.

  NCT03529045· LivaNova· Source

• Completed

  TRAMmoniTTR Study Genetic Screening of an At-risk Population for hATTR and Monitoring of TTR Positive Subjects

  NCT03237494· CENTOGENE GmbH Rostock· Source

• Completed

  HD21

  NCT02661503· Phase 3· University Of Cologne· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Chronic spontaneous urticaria4 works · 0 trials
• Keratoconus4 works · 0 trials